跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Can AI Discover New Drugs? A High-Level Overview

1Why Drug Discovery Is Hard, and Where AI Fits2How AI Learns From Molecules and Proteins3Finding and Validating a Biological Target4Designing Molecules: Generative AI and Virtual Screening5From Hit to Lead: Optimizing Properties With AI6What AI Still Cannot Do7Judging the Claims: Real Successes, Failures, and Open Questions
Why Drug Discovery Is Hard, and Where AI Fits

Why Almost Everything Fails

2 / 4
Follow the funnel from the wide top to the narrow bottom. The width at each level is the number of compounds still alive. Most of the narrowing happens near the top, where compounds are cheap to make and cheap to discard. But look at the last few levels — the survivors there are few, and each one represents years of investment. When a compound fails at that depth, the entire accumulated cost is written off. That is why the field cares less about making the early stages faster and more about making the late predictions more trustworthy.
0:00 / 0:00

The pipeline diagram makes the process look orderly, but the numbers behind it are brutal. For every medicine that reaches patients, thousands of compounds are made and tested, and the great majority are discarded. The narrowing is not uniform: most compounds are eliminated early and cheaply, during hit finding and lead optimization, but a meaningful fraction survives all the way to human trials and then fails there, where each failure costs far more.

This pattern is called attrition, meaning the rate at which candidates drop out of the pipeline. Attrition is the central economic fact of drug discovery. Because the cost of the late failures must be carried by the few successes, the average cost of bringing one approved drug to market is commonly estimated in the range of one to several billion dollars, and the timeline from first target work to approval typically runs ten to fifteen years.

The practical consequence is that reducing late-stage attrition is worth far more than reducing early-stage cost. A method that eliminates a thousand compounds in the laboratory saves relatively little; a method that correctly predicts which of two candidates will fail in phase 3 saves an enormous amount. This asymmetry is the reason the field pays so much attention to any tool that might improve the reliability of early predictions.

上一页2 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion